Chronic Endometritis and Recurrent Implantation Failure
Conditions
Interventions
Antibiotics group :Doxycycline Hyclate combined with metronidazole
Combined therapy group :WYHZ combined with antibiotics
TCM group:WYHZ formula
D&M TCM and Antibiotics WYHZ
Sponsors
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Eligibility
Sex/Gender
Female
Age
25 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1) Be between the ages of 25-40 years. 2) meeting the diagnostic criteria for CE and RIF. 3) TCM evidence consistent with spleen and kidney yang deficiency and internal dampness. 4) having transferable D3-day high-quality frozen embryos (7-9 embryonic cells on day 3 after fertilization, 10% fragmentation, with stage-stage specific cell size and no multinucleation) or frozen blastocysts (=3BB). 5) estrogen and progestin replacement therapy (HRT) with an endometrial thickness of =7 mm on the day of endometrial transformation. 6) voluntarily subjected to the trial and agreed to sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1) Those who are ready to undergo PGD. 2) Those receiving donor eggs. 3) chromosomal abnormalities (excluding chromosomal polymorphisms) in both or one of the spouses. 4) Patients with known embryonic factors leading to implantation failure. 5) uterine pathologies that may affect implantation (including uterine malformations, uterine tuberculosis, history of uterine adhesions, submucosal fibroids, adenomyosis, >4 cm interstitial myomas) 6) recurrent spontaneous abortion (2 or more fetal losses before 28 weeks of gestation) 7) combined with other endocrine disorders such as thyroid disease, hyperprolactinemia, insulin resistance, diabetes mellitus, adrenal disease, etc., with poorly controlled hormone levels in the last 3 months (8) clearly diagnosed autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, antiphospholipid syndrome, etc. 9) those with untreated hydrocele in the fallopian tubes 10) Those who are allergic to the drugs in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Live birth rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| HCG positivity rate;clinical pregnancy rate;ongoing pregnancy rate; | — |
Countries
China
Contacts
Public ContactXia Tian
Outcome results
None listed